<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL document created with XMark (C) by Bowne Inc. -->
<!-- Based on XBRL 2.1 -->
<!--merged on: 11/5/2009 12:16:00 AM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:jnj="http://jnj.com/2009-09-27" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://xbrl.us/us-gaap/2009-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.us/dei/2009-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="jnj-20090927.xsd" />
  <!-- Context Section -->
  <context id="BalanceAsOf_28Sep2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <instant>2008-09-28</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Dec2007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <instant>2007-12-30</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_27Sep2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <startDate>2009-06-29</startDate>
      <endDate>2009-09-27</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_28Sep2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <startDate>2008-06-30</startDate>
      <endDate>2008-09-28</endDate>
    </period>
  </context>
  <context id="NineMonthsEnded_28Sep2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <startDate>2007-12-31</startDate>
      <endDate>2008-09-28</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_27Sep2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <instant>2009-09-27</instant>
    </period>
  </context>
  <context id="BalanceAsOf_28Dec2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <instant>2008-12-28</instant>
    </period>
  </context>
  <context id="BalanceAsOf_25Oct2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <instant>2009-10-25</instant>
    </period>
  </context>
  <context id="December-29-2008_September-27-2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
    </entity>
    <period>
      <startDate>2008-12-29</startDate>
      <endDate>2009-09-27</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!-- Element Section -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;div align="left"&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;NOTE 1 &amp;#8212;
   The accompanying unaudited interim consolidated financial statements and related notes
   should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp;#038;
   Johnson and its Subsidiaries (the &amp;#8220;Company&amp;#8221;) and related
   notes as contained in the Company&amp;#8217;s Annual
   Report on Form 10-K for the fiscal year ended December&amp;#160;28, 2008. The unaudited interim financial
   statements include all adjustments (consisting only of normal recurring adjustments) and accruals
   necessary in the judgment of management for a fair statement of the results for the periods
   presented.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal third quarter of 2009, the Company adopted &lt;i&gt;The FASB Accounting Standards
   Codification (ASC or Codification) and the Hierarchy of Generally Accepted Accounting Principles
   (GAAP) &lt;/i&gt;which establishes the Codification as the sole source for authoritative U.S. GAAP and will
   supersede all accounting standards in U.S. GAAP, aside from those issued by the SEC. The adoption
   of the Codification did not have an impact on the Company&amp;#8217;s results of operations, cash flows or
   financial position. Since the adoption of the Accounting Standards Codification (ASC)&amp;#160;the Company&amp;#8217;s
   notes to the consolidated financial statements will no longer make reference to Statement of
   Financial Accounting Standards (SFAS)&amp;#160;or other U.S. GAAP pronouncements.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal second quarter of 2009, in accordance with U.S. GAAP, the Company adopted the
   standards on subsequent events. This pronouncement establishes standards of accounting for and
   disclosure of events that occur after the balance sheet date but before financial statements are
   issued. See Note 13 for additional information.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the
   standards on business combinations and &lt;i&gt;n&lt;/i&gt;oncontrolling interests in Consolidated Financial
   Statements. These statements aim to improve, simplify, and converge internationally, the accounting
   for business combinations and the reporting of noncontrolling interests in consolidated financial
   statements. These statements have a significant impact on the manner in which the Company accounts
   for acquisitions beginning in the fiscal year 2009. Significant changes include the capitalization
   of in process research and development (IPR&amp;#038;D), expensing of acquisition related restructuring
   actions and transaction related costs and the recognition of contingent purchase price
   consideration at fair value at the acquisition date. In addition, changes in accounting for
   deferred tax asset valuation allowances and acquired income tax uncertainties after the measurement
   period will be recognized in earnings rather than as an adjustment to the cost of acquisition. This
   accounting treatment for taxes is applicable to acquisitions that occurred
   both prior and subsequent to the adoption of the standard. Operating profit attributable to noncontrolling
       interests are reported in Other (Income)Expense, net and the related tax impact to the Provision
       for Taxes. Additionally, equity attributable to noncontrolling interests is recorded in Other
       Non-Current liabilities. Noncontrolling interests as related to the Company&amp;#8217;s financial statements
       are immaterial and therefore, not separately disclosed. The adoption of these standards did not
       have a material impact on the Company&amp;#8217;s results of operations, cash flows or financial position.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the
       standard related to disclosures about derivative instruments and hedging activities, to enhance the
       disclosure regarding the Company&amp;#8217;s derivative and hedging activities to improve the transparency of
       financial reporting. The adoption of this standard did not have a significant impact on the Company&amp;#8217;s results of operations, cash flows or
       financial position. See Note 2 for enhanced disclosures.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the
       standard on collaborative arrangements related to the development and commercialization of
       intellectual property. This standard addresses the income statement classification of payments made
       between parties in a collaborative arrangement.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or
       biotechnology companies, to develop and commercialize drug candidates or intellectual property.
   These arrangements typically involve two (or more) parties who are active participants in the
       collaboration and are exposed to significant risks and rewards dependent on the commercial success
       of the activities. These collaborations usually involve various activities by one or more parties,
       including research and development, marketing and selling and distribution. Often, these
       collaborations require upfront, milestone and royalty or profit share payments, contingent upon the
       occurrence of certain future events linked to the success of the asset in development. Amounts due
       from collaborative partners related to development activities are generally reflected as a
       reduction of research and development expense because the performance of contract development
       services is not central to the Company&amp;#8217;s operations. In general, the income statement presentation
       for these collaborations is as follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="48%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="46%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;&lt;b&gt;Nature / Type of Collaboration&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;&lt;b&gt;Statement of Earnings Presentation&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Third party sale of product
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;Sales to customers&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Royalties / milestones paid to
   collaborative partner (post-regulatory
   approval)*
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;Cost of goods sold&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Royalties received from collaborative partner
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;Other income (expense), net&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Upfront payments &amp;#038; milestones paid to
   collaborative partner (pre-regulatory
   approval)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;Research expense&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Research and development payments to
   collaborative partner
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;Research expense&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Research and development payments
   received from collaborative partner
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right" valign="top"&gt;Reduction of Research expense&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Milestones are capitalized as intangible assets and amortized to cost of goods sold over the
   useful life.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The impact of the adoption of this standard related to all collaboration agreements that existed as
       of September&amp;#160;27, 2009 and December&amp;#160;28, 2008 was immaterial to the Company&amp;#8217;s results of operations,
       cash flows or financial position.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2009, in accordance with U.S. GAAP, the Company adopted the
       standard related to defensive intangible assets. This standard applies to
       acquired intangible assets in situations in which an entity does not intend to actively use the
       asset but intends to hold the asset to prevent others from obtaining access to the asset, except
       for intangible assets that are used in research and development activities. The adoption of this
       standard did not have a significant impact on the Company&amp;#8217;s results of operations, cash flows or
       financial position.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2008, in accordance with U.S. GAAP, the Company adopted the
       standard related to fair value measurements except for non-financial assets and liabilities
       recognized or disclosed at fair value on a non-recurring basis, which became effective during the
       first fiscal quarter of 2009. The effect of adoption on December&amp;#160;29, 2008 of this standard for
       non-financial assets and liabilities recorded at fair value on a nonrecurring basis did not have a
       material impact on the Company&amp;#8217;s financial position and results of operations.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:FairValueDisclosuresTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 2 &amp;#8212; FINANCIAL INSTRUMENTS
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2009, in accordance with U.S. GAAP the Company adopted the
   standard related to disclosures about derivative instruments and hedging activities. This standard
   requires qualitative disclosures about objectives and strategies for using derivatives,
   quantitative disclosures about fair value amounts of gain and losses on derivative instruments, and
   disclosures about credit-risk-related contingent features in derivative agreements.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The Company uses forward exchange contracts to manage its exposure to the variability of cash
   flows, primarily related to the foreign exchange rate changes of future intercompany product and
   third- party purchases of raw materials denominated in foreign currency. The Company also uses
   cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both
   types of derivatives are designated as cash flow hedges. The Company also uses forward exchange
   contracts to manage its exposure to the variability of cash flows for repatriation of foreign
   dividends. These contracts are designated as net investment hedges. Additionally, the Company
   uses forward exchange contracts to
   offset its exposure to certain foreign currency assets and
       liabilities. These forward exchange contracts are not designated as hedges and therefore, changes
       in the fair values of these derivatives are recognized in earnings, thereby offsetting the current
       earnings effect of the related foreign currency assets and liabilities. The Company does not enter
       into derivative financial instruments for trading or speculative purposes, or contain credit risk
       related contingent features or requirements to post collateral. On an ongoing basis the Company
       monitors counterparty credit ratings. The Company considers credit non-performance risk to be low,
       because the Company enters into agreements with commercial institutions that have at least an A (or
       equivalent) credit rating. As of September&amp;#160;27, 2009, the Company had notional amounts outstanding
       for forward foreign exchange contracts and cross currency interest rate swaps of $23&amp;#160;billion and $4
   billion, respectively.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;As
       required by the ASC for derivative instruments and hedging activities, all derivative instruments
       are to be recorded on the balance sheet at fair value. Changes in the fair value of derivatives are
       recorded each period in current earnings or other comprehensive income, depending on whether the
       derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The designation as a cash flow hedge is made at the entrance date into the derivative contract. At
       inception, all derivatives are expected to be highly effective. Changes in the fair value of a
       derivative that is designated as a cash flow hedge and is highly effective are recorded in
       accumulated other comprehensive income until the underlying transaction affects earnings, and are
       then reclassified to earnings in the same account as the hedged transaction. Gains/losses on net
       investment hedges are accounted for through the currency translation account and are insignificant.
   On an ongoing basis, the Company assesses whether each derivative continues to be highly effective
       in offsetting changes in the cash flows of hedged items. If and when a derivative is no longer
       expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any,
       is included in current period earnings in other (income)&amp;#160;and expense, net, and was insignificant
       for the fiscal quarters and fiscal nine months ended September&amp;#160;27, 2009 and September&amp;#160;28, 2008.
   Refer to Note 8 for disclosures of movements in Accumulated Other Comprehensive Income.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;As of September&amp;#160;27, 2009, the balance of deferred net gains on derivatives included in accumulated
       other comprehensive income was $48&amp;#160;million after-tax. For additional information, see Note 8. The
       Company expects that substantially all of the amount related to foreign exchange contracts will be
       reclassified into earnings over the next 12&amp;#160;months as a result of transactions that are expected to
       occur over that period. The maximum length of time over which the Company is hedging transaction
       exposure is 18&amp;#160;months. The amount ultimately realized in earnings will differ as foreign exchange
       rates change. Realized gains and losses are ultimately determined by actual exchange rates at
       maturity of the derivative.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The following table is a summary of the activity for the fiscal third quarter and fiscal nine
       months ended September&amp;#160;27, 2009 related to designated derivatives as defined in the codification:
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;(Dollars in Millions)
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="37%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Gain/ (Loss)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Gain/ (Loss)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;recognized in&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;reclassed from&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Gain/ (Loss)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Accumulated OCI&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;recognized in&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Cash Flow Hedges&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;OCI&lt;/b&gt; &lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/sup&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;into income&lt;/b&gt; &lt;sup style="font-size: 85%; vertical-align: text-top"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/sup&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;income&lt;/b&gt; &lt;sup style="font-size: 85%; vertical-align: text-top"&gt;(2)&lt;/sup&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Nine&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Nine&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Nine&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Quarter&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Months&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Quarter&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Months&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Quarter&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Months&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;ended&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;Ended&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;ended&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;Ended&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;ended&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;Ended&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;27&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(19&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(14&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(A)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(E)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(124&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(189&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;37&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(B)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(E)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(23&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(7&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;22&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(C)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(E)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cross currency interest rate swaps
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(49&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;144&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(21&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(D)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(E) &lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(11&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;22&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(E)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(11&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(10&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;sub style="font-size: 85%; vertical-align: text-bottom"&gt;(E)&lt;/sub&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(180&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(49&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(20&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;24&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(10&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(5&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(1)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Effective portion&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(2)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Ineffective portion&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(A)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Included in Sales to customer&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(B)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Included in Cost of products sold&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(C)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Included in Research expense&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(D)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Included in Interest (Income)/Interest Expense, net&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(E)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Included in Other (Income)/Expense, net&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;For the fiscal quarter and the fiscal nine months ended September&amp;#160;27, 2009, a gain of $16&amp;#160;million
       and $20&amp;#160;million, respectively, was recognized in Other (income)/expense, net, relating to foreign
       exchange contracts not designated as hedging instruments under the codification.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2008, in accordance with U.S. GAAP, the Company adopted the
       standard related to fair value measurements except for non-financial assets and liabilities
       recognized or disclosed at fair value on a non-recurring basis, which became effective during the
       first fiscal quarter of 2009. The effect of adoption on December&amp;#160;29, 2008 of this standard for
       non-financial assets and liabilities recorded at fair value on a nonrecurring basis did not have a
       material impact on the Company&amp;#8217;s financial position and results of operations. This standard
       defines fair value, establishes a framework for measuring fair value and expands disclosures about
       fair value measurements. During the fiscal first quarter of 2008, the Company adopted the standard
       related to fair value option for financial assets and financial liabilities&lt;i&gt;. &lt;/i&gt;This
       standard permits the Company to
   measure certain financial assets and financial liabilities at fair
       value. The Company assessed the fair value option made available upon adopting this standard, and
       has elected not to apply the fair value option to any financial instruments that were not already
       recognized at fair value.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The ASC defines fair value as the exit price that would be received to sell an asset or paid to
       transfer a liability. Fair value is a market-based measurement that should be determined using
       assumptions that market participants would use in pricing an asset or liability. The authoritative
       literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair
       value. The levels within the hierarchy are described in the table below with level 1 having the
       highest priority and level 3 having the lowest.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The fair value of a derivative financial instrument (i.e. forward exchange contract, currency swap)
   is the aggregation by currency of all future cash flows discounted to its present value at the
       prevailing market interest rates and subsequently converted to the U.S. dollar at the current spot
       foreign exchange rate. The Company does not believe that fair values of these derivative
       instruments materially differ from the amounts that could be realized upon settlement or maturity,
       or that the changes in fair value will have a material effect on the Company&amp;#8217;s results of
       operations, cash flows or financial position. The Company also holds equity investments which are
       classified as level 1 since they are traded in an active exchange market. The Company did not have
       any other significant financial assets or liabilities which would require revised valuations under
       this standard that are recognized at fair value.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The Company&amp;#8217;s significant financial assets and liabilities measured at fair value as of September
       27, 2009 were as follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Quoted prices&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;in active&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Significant&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;markets for&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;other&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Significant&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;identical&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;observable&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;unobservable&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;assets&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;inputs&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;inputs&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Derivatives designated as hedging instruments :&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Other Assets:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;511&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cross currency interest rate swaps
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;144&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Total&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;655&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Other Liabilities:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;906&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cross currency interest rate swaps
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;749&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Total&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,655&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Derivatives not designated as hedging instruments :&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Other Assets:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;52&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Other Liabilities:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Foreign exchange contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;53&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Other Equity Investments&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;821&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;Financial Instruments not measured at Fair Value:&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;b&gt;The
       following financial assets and liabilities are held at carrying amount on the consolidated
       balance sheet:&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Carrying&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Estimated&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Amount&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Fair Value&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Financial Assets&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Current Investments&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,356&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,356&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Government securities and obligations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8,571&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8,572&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate debt securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;268&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;268&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Money market funds
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,359&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,359&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Time deposits
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;783&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;783&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total cash, cash equivalents and current marketable securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;14,337&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;14,338&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Non-Current Investments&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Marketable securities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;19&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;19&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Financial Liabilities&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Current Debt&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,341&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,341&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Non-Current Debt&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;5.15% Debentures due 2012
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;600&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;658&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;3.80% Debentures due 2013
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;500&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;534&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;5.55% Debentures due 2017
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,127&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;5.15% Debentures due 2018
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;898&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;995&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;4.75% Notes due 2019 (1B Euro 1.4796)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,470&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,574&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;3% Zero Coupon Convertible Subordinated Debentures due in 2020
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;188&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;229&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;6.73% Debentures due 2023
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;250&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;299&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;5.50% Notes
   due 2024 (500 GBP 1.6210)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;803&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;878&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;6.95% Notes due 2029
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;294&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;363&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;4.95% Debentures due 2033
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;500&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;470&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;5.95% Notes due 2037
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;995&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,175&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;5.86% Debentures due 2038
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;700&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;792&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other (Includes Industrial Revenue Bonds)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;61&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;61&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total Non-Current Debt
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;8,259&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;9,155&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The weighted average effective rate on non-current debt is 5.42%.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Fair value of government securities and obligations and non-current marketable securities was
       estimated using quoted broker prices in active markets.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Fair value of the non-current debt was estimated using market prices, which were corroborated by
       quoted broker prices in active markets.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:IncomeTaxDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 3 &amp;#8212; INCOME TAXES
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The worldwide effective income tax rates for the fiscal nine months of 2009 and 2008 were 23.5% and
   23.7%, respectively. The lower effective tax rate was primarily due to the U.S. Research tax
   credit which was not in effect in the first fiscal nine months of 2008.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:InventoryDisclosureTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:InventoryDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 4 &amp;#8212; INVENTORIES
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;September 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;December 28,&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;2008&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Raw materials and supplies
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;824&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;839&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Goods in process
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,554&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,372&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Finished goods
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,190&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,841&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,568&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,052&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:InventoryDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 5 &amp;#8212; INTANGIBLE ASSETS AND GOODWILL
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Intangible assets that have finite useful lives are amortized over their estimated useful lives.
   The latest impairment assessment of goodwill and indefinite lived intangible assets was completed
   in the fiscal fourth quarter of 2008. Future impairment tests for goodwill and indefinite lived
   intangible assets will be performed annually in the fiscal fourth quarter, or sooner if warranted.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;September 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;December 28,&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;2008&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Trademarks
   (non-amortizable) &amp;#8212; gross
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6,128&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,879&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less accumulated amortization
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;147&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;145&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Trademarks
   (non-amortizable) &amp;#8212; net
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,981&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,734&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Patents and trademarks &amp;#8212; gross
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,704&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,119&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less accumulated amortization
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,106&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,820&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Patents and
   trademarks &amp;#8212; net
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,598&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,299&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other amortizable intangibles &amp;#8212; gross
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8,090&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,376&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less accumulated amortization
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,701&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,433&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other
   intangibles &amp;#8212; net
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,389&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,943&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Purchased in process research and
   development (non&amp;#8212;amortizable) &amp;#8212; gross*
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,668&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total intangible assets &amp;#8212; gross
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21,590&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;18,374&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less accumulated amortization
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,954&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,398&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total intangible assets &amp;#8212; net
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;16,636&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;13,976&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Purchased in process research and development will be accounted for as an indefinite-lived
   intangible asset until regulatory approval or discontinuation.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Goodwill as of September&amp;#160;27, 2009 was allocated by segment of business as follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Med Dev&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;Consumer&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;Pharm&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&amp;#038; Diag&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;Total&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Goodwill, net
   at December&amp;#160;28, 2008
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,474&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;963&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,282&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;13,719&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Acquisitions
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;284&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;376&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;660&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Translation &amp;#038; Other**
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;754&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(133&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;638&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Goodwill, net as of
   September&amp;#160;27, 2009
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;8,228&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,264&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,525&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;15,017&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;**&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Includes currency translation, reclassification between segments and other adjustments.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The weighted average amortization periods for patents and trademarks and other intangible assets
       are 16&amp;#160;years and 28&amp;#160;years, respectively. The amortization expense of amortizable intangible assets
       for the fiscal nine months ended September&amp;#160;27, 2009 was $509&amp;#160;million, and the estimated
       amortization expense for the five succeeding years approximates
   $750&amp;#160;million, per year.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;/div&gt;
</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:SegmentReportingDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;NOTE 6 &amp;#8212; SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS&lt;br /&gt;
   &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(Dollars in Millions)
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;SALES BY SEGMENT OF BUSINESS (1)
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="11" style="border-bottom: 0px solid #000000"&gt;Fiscal Quarters Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Percent&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;Change&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Consumer
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,691&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,769&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(4.4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,298&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,330&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1.4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,989&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,099&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2.7&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Pharmaceutical
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,857&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,538&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(19.2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,392&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,575&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(7.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,249&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6,113&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Medical Devices &amp;#038;
   Diagnostics
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,766&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,648&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4.5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,077&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,061&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;0.5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,843&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,709&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Worldwide
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,314&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,955&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(8.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,767&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,966&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2.5&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;15,081&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;15,921&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(5.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="11" style="border-bottom: 0px solid #000000"&gt;Fiscal Nine Months Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Percent&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Change&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Consumer
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,125&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5,282&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(3.0&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6,429&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6,917&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(7.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11,554&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12,199&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(5.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Pharmaceutical
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9,703&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11,401&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14.9&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6,824&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,481&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(8.8&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16,527&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;18,882&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(12.5&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Medical Devices &amp;#038;
   Diagnostics
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8,194&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,959&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3.0&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9,071&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9,525&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(4.8&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17,265&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17,484&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Worldwide
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;23,022&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;24,642&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(6.6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;International
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;22,324&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;23,923&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(6.7&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;45,346&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;48,565&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(6.6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(1)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Export sales are not significant.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;OPERATING PROFIT BY SEGMENT OF BUSINESS
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="11" style="border-bottom: 0px solid #000000"&gt;Fiscal Quarters Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Percent&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Change&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Consumer
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;812&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;764&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Pharmaceutical
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,637&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,003&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(18.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Medical Devices
   &amp;#038; Diagnostics
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,016&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,657&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21.7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Segments total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,465&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,424&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(0.9&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expense not allocated to
   segments (2)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(220&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(134&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Worldwide total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;4,245&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;4,290&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1.0&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="11" style="border-bottom: 0px solid #000000"&gt;Fiscal Nine Months Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Percent&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Change&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Consumer
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,307&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,175&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Pharmaceutical
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,595&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6,513&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Medical Devices
   &amp;#038; Diagnostics (1)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,891&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5,159&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;14.2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Segments total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;13,793&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;13,847&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(0.4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expense not allocated to
   segments (2)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(642&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(435&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Worldwide total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;13,151&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;13,412&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1.9&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(1)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Includes $40&amp;#160;million of in-process research and development (IPR&amp;#038;D) charges related to the
   acquisition of Amic AB completed in the fiscal second quarter of 2008.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(2)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Amounts not allocated to segments include interest income/(expense) and general corporate
   income/(expense).&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;SALES BY GEOGRAPHIC AREA&lt;br /&gt;
   (Dollars in Millions)
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="11" style="border-bottom: 0px solid #000000"&gt;Fiscal Quarters Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Percent&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Change&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,314&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7,955&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(8.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Europe
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,879&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,076&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(4.8&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Western Hemisphere,
   excluding U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,338&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,461&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(8.4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Asia-Pacific, Africa
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,550&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,429&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5.0&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;15,081&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;15,921&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(5.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="11" style="border-bottom: 0px solid #000000"&gt;Fiscal Nine Months Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Percent&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Change&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;23,022&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;24,642&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(6.6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Europe
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11,522&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12,931&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(10.9&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Western Hemisphere,
   excluding U.S.
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,615&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,986&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(9.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Asia-Pacific, Africa
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,187&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7,006&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Total
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;45,346&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;48,565&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(6.6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:EarningsPerShareTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:EarningsPerShareTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 7 &amp;#8212; EARNINGS PER SHARE
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share
   for the fiscal third quarters ended September&amp;#160;27, 2009 and September&amp;#160;28, 2008.
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"&gt;Fiscal Quarters Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;September 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;September 28,&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Shares in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Basic net earnings per share
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1.21&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1.19&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Average
   shares outstanding &amp;#8212; basic
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,756.3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,790.9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Potential shares exercisable under
   stock option plans
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;174.5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;242.0&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less: shares which could be
   repurchased under treasury stock
   method
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(141.4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(205.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Convertible debt shares
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3.6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3.7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Average
   shares outstanding &amp;#8212; diluted
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,793.0&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,831.3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Diluted earnings per share
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1.20&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1.17&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The diluted earnings per share calculation for the fiscal third quarters ended September&amp;#160;27, 2009
   and September&amp;#160;28, 2008 included the dilutive effect of convertible debt that was offset by the
   related reduction in interest expense.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The diluted earnings per share calculation for the fiscal third quarter ended September&amp;#160;27, 2009
   excluded 77&amp;#160;million shares related to stock options, as the exercise price of these options was
   greater than their average market value, which would result in an anti-dilutive effect on diluted
   earnings per share. For the fiscal third quarter ended September&amp;#160;28, 2008 the number of shares
   related to stock options for which the exercise price of these options was greater than their
   average market value was insignificant.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share
   for the fiscal nine months ended September&amp;#160;27, 2009 and September&amp;#160;28, 2008.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"&gt;Fiscal Nine Months Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;September 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;September 28,&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Shares in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Basic net earnings per share
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3.64&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3.64&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Average
   shares outstanding &amp;#8212; basic
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,760.0&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,811.9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Potential shares exercisable under
   stock option plans
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;103.9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;241.5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less: shares which could be
   repurchased under treasury stock
   method
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(79.6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(209.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Convertible debt shares
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3.6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3.7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Average
   shares outstanding &amp;#8212; diluted
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,787.9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,847.8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Diluted earnings per share
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3.61&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3.60&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The diluted earnings per share calculation for both the fiscal nine months ended September&amp;#160;27, 2009
   and September&amp;#160;28, 2008 included the dilutive effect of convertible debt that was offset by the
       related reduction in interest expense.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The diluted earnings per share calculation for the fiscal nine months ended September&amp;#160;27, 2009 and
       September&amp;#160;28, 2008, excluded 148&amp;#160;million shares and 1&amp;#160;million shares, respectively, related to
       stock options as the exercise price of these options was greater than their average market value,
       which would result in an anti-dilutive effect on diluted earnings per share.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:EarningsPerShareTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 8 - us-gaap:ComprehensiveIncomeNoteTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 8 &amp;#8212; ACCUMULATED OTHER COMPREHENSIVE INCOME
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Total comprehensive income for the fiscal nine months ended September&amp;#160;27, 2009 was $12.3&amp;#160;billion,
   compared with $10.0&amp;#160;billion for the same period a year ago. Total comprehensive income for the
   fiscal third quarter ended September&amp;#160;27, 2009 was $5.1&amp;#160;billion, compared with $1.8&amp;#160;billion for the
   same period a year ago. Total comprehensive income included net earnings, net unrealized currency
   gains and losses on translation, adjustments related to Employee Benefit Plans, net unrealized
   gains and losses on securities available for sale and net gains and losses on derivative
   instruments qualifying and designated as cash flow hedges. The following table sets forth the
   components of accumulated other comprehensive income.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="40%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Total&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Unrld&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Gains/&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Accum&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;For.&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Gains/&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Employee&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;(Losses)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Other Comp&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Cur.&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;(Losses)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Benefit&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;on Deriv&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Inc/&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Trans.&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;on Sec&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Plans&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#038; Hedges&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;(Loss)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;December&amp;#160;28, 2008
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(1,871&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;25&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(3,230&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;121&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(4,955&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2009 nine months change
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Net change associated
   with current period
   hedging transactions
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(28&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Net amount reclassed to
   net earnings
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(45&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;) *&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Net nine months change
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,268&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(10&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;109&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(73&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,294&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;September&amp;#160;27, 2009
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;397&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;15&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(3,121&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;48&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2,661&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Substantially offset in net earnings by changes in value of the underlying transactions.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact.
   Foreign currency translation adjustments are not currently adjusted for income taxes as they relate
       to permanent investments in international subsidiaries.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <jnj:MergersAcquisitionsDivestituresDisclosureTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 9 - jnj:MergersAcquisitionsDivestituresDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 9 &amp;#8212; BUSINESS COMBINATIONS AND DIVESTITURES
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the
   fiscal third quarter of 2009, the Company acquired
   substantially all of the assets and
   rights of Elan&amp;#8217;s Alzheimer&amp;#8217;s Immunotherapy Program through a newly formed company, of which Johnson
   &amp;#038; Johnson owns 50.1% and Elan owns 49.9%. In addition, the
   Company purchased approximately 107 million newly issued American
   Depositary Receipts (ADRs) of Elan, representing 18.4% of Elan&amp;#8217;s
   outstanding ordinary shares. As part of this transaction, Johnson
   &amp;#038; Johnson paid $0.9 billion to Elan and committed to fund up to
   $0.2 billion of Elan&amp;#8217;s share of research and development
   spending by the newly formed company. Of this total consideration of
   $1.1 billion, $0.8 billion represents the fair value of the 18.4%
   investment in Elan based on Elan&amp;#8217;s share price in an actively
   traded market as of the date of this transaction. The remaining $0.3
   billion represents the consideration for Johnson &amp;#038;
   Johnson&amp;#8217;s 50.1% interest in the newly formed company. This
   transaction resulted in acquired in-process research and development
   (IPR&amp;#038;D) for $0.7 billion and a noncontrolling interest of $0.6
   billion, which Johnson &amp;#038; Johnson has recorded in other
   non-current liabilities.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal third quarter of 2009, the Company acquired Cougar Biotechnology, Inc., a
   development stage biopharmaceutical company with specific focus on oncology, for a net purchase
   price of $1.0&amp;#160;billion. The purchase price for the acquisition was allocated primarily to purchased
   IPR&amp;#038;D for $1.0&amp;#160;billion, goodwill for $0.3&amp;#160;billion and deferred tax liability for $0.3&amp;#160;billion.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal first quarter of 2009, the Company acquired Mentor Corporation, a leading
   supplier of medical products for the global aesthetic market, for a net purchase price of $1.1
   billion. The purchase price for the acquisition was allocated primarily to amortizable intangible
   assets for $0.9&amp;#160;billion and goodwill for $0.4&amp;#160;billion.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal third quarter of 2008 the Company acquired Beijing Dabao Cosmetics Co., Ltd., a
   company that sells personal care brands in China.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;During the fiscal second quarter of 2008, the Company acquired Amic AB for a purchase price of $44
   million in cash and debt. Amic AB is a Swedish developer of in vitro diagnostic technologies for
       use in point-of-care and near-patient settings (outside the physical facilities of the clinical
       laboratory). An in-process research &amp;#038; development (IPR&amp;#038;D) charge of $40&amp;#160;million before and after
       tax was recorded related to the acquisition of Amic AB.
   &lt;/div&gt;
   &lt;/div&gt;
</jnj:MergersAcquisitionsDivestituresDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 10 - us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;NOTE 10 &amp;#8212; PENSIONS AND OTHER POSTRETIREMENT BENEFITS
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Components of Net Periodic Benefit Cost
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Net periodic benefit cost for the Company&amp;#8217;s defined benefit retirement plans and other benefit
   plans for the fiscal third quarters of 2009 and 2008 include the following components:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"&gt;Retirement Plans&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"&gt;Other Benefit Plans&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="15" style="border-bottom: 0px solid #000000"&gt;Fiscal Quarters Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Service cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;114&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;126&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;33&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;35&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Interest cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;188&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;177&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;43&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;43&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected return on
   plan assets
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(240&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(220&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Amortization of prior
   service cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Recognized actuarial
   losses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;35&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;13&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;15&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Curtailments and
   settlements
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(11&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net periodic benefit cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;90&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;101&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;87&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;91&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Net periodic benefit cost for the Company&amp;#8217;s defined benefit retirement plans and other benefit
   plans for the fiscal nine months of 2009 and 2008 include the following components:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"&gt;Retirement Plans&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 0px solid #000000"&gt;Other Benefit Plans&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="15" style="border-bottom: 0px solid #000000"&gt;Fiscal Nine Months Ended&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 27,&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Sept. 28,&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 0px solid #000000"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2009&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;2008&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Service cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;348&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;381&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;103&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;106&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Interest cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;555&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;534&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;128&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;126&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected return on
   plan assets
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(695&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(666&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Amortization of prior
   service cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(4&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Amortization of net
   transition asset
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Recognized actuarial
   losses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;117&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;47&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;41&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;48&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Curtailments and
   settlements
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(11&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net periodic benefit cost
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;324&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;309&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;267&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;274&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Company Contributions
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;For the fiscal nine months ended September&amp;#160;27, 2009, the Company contributed $828&amp;#160;million and $19
   million to its U.S. and international retirement plans, respectively. In 2006, Congress passed the
       Pension Protection Act of 2006. The Act amended the Employee Retirement Income Security Act (ERISA)
   for plan years beginning after 2007 and established new minimum funding standards for U.S. employer
       defined benefit plans. The Company plans to continue to fund its U.S. defined benefit plans to
       comply with the Pension Protection Act of 2006. International plans are funded in accordance with
       local regulations.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 11 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;NOTE 11 &amp;#8212; RESTRUCTURING
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In the third quarter of 2007, the Company announced restructuring initiatives in an effort to
   improve its overall cost structure. This action was taken to offset the anticipated negative
   impacts associated with generic competition in the Pharmaceutical segment and challenges in the
   drug-eluting stent market. The Company&amp;#8217;s Pharmaceuticals segment has reduced its cost base by
   consolidating certain operations, while continuing to invest in recently launched products and its
   late-stage pipeline of new products. The Cordis franchise has moved to a more integrated business
   model to address the market changes underway with drug-eluting stents and to better serve the broad
   spectrum of its patients&amp;#8217; cardiovascular needs, while reducing its cost base. This program allowed
   the Company to accelerate steps to standardize and streamline certain aspects of its
   enterprise-wide functions such as human resources, finance and information technology to support
   growth across the business, while also leveraging its scale more effectively in areas such as
   procurement to benefit its operating companies. Additionally, as part of this initiative, the
   Company eliminated approximately 4,200 positions.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The Company recorded $745&amp;#160;million in pre-tax charges during the fiscal third quarter of 2007, of
   which, approximately, $500&amp;#160;million of the pre-tax restructuring charges required cash payments. The
   $745&amp;#160;million of restructuring charges included severance costs of $450&amp;#160;million, asset
   write-offs of $272&amp;#160;million and $23&amp;#160;million related to leasehold obligations. The $272&amp;#160;million of
   asset write-offs related to property, plant and equipment of $166&amp;#160;million, intangible assets of $48
   million and other assets of $58&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The following table summarizes the severance reserve and the associated spending under this
   initiative through the third quarter of 2009:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="88%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(Dollars in Millions)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;Severance&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Reserve balance as of:
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;December&amp;#160;28, 2008
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;178&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash outlays
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(108&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;September&amp;#160;27, 2009*
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;70&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Substantially all cash outlays related to the remaining reserve balance for severance is expected
   to be paid out in the fourth quarter of 2009 in accordance with the Company&amp;#8217;s plans and local laws.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <jnj:LegalProceedingsTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 12 - jnj:LegalProceedingsTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;NOTE 12 &amp;#8212; LEGAL PROCEEDINGS
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;PRODUCT LIABILITY
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The Company&amp;#8217;s subsidiaries are involved in numerous product liability cases in the United States,
   many of which concern alleged adverse reactions to drugs and medical devices. The damages claimed
   are substantial, and while the Company is confident of the adequacy of the warnings and
   instructions for use that accompany such products, it is not feasible to predict the ultimate
   outcome of litigation. However, the Company believes that if any product liability results from
   such cases, it will be substantially covered by existing amounts accrued in the Company&amp;#8217;s balance
   sheet and, where available, by third-party product liability insurance.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Multiple products of Johnson &amp;#038; Johnson subsidiaries are subject to numerous product liability
   claims and lawsuits, including ORTHO EVRA&amp;#174;, RISPERDAL&amp;#174;, DURAGESIC&amp;#174;, LEVAQUIN&amp;#174;, the CYPHER&amp;#174; Stent
   and the CHARIT&amp;#201;&amp;#8482; Artificial Disc. There are approximately 467 claimants who have pending lawsuits
   or claims regarding injuries allegedly due to ORTHO EVRA&amp;#174;, 425 with respect to RISPERDAL&amp;#174;, 280
   with respect to CHARIT&amp;#201;&amp;#8482;, 276 with respect to LEVAQUIN&amp;#174;, 110 with respect to DURAGESIC&amp;#174; and 63 with
   respect to CYPHER&amp;#174;. These claimants seek substantial compensatory and, where available, punitive
   damages.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;With respect to RISPERDAL&amp;#174;, the Attorneys General of eight states and the Office of General Counsel
   of the Commonwealth of Pennsylvania have filed actions seeking reimbursement of Medicaid or other
   public funds for RISPERDAL&amp;#174; prescriptions written for off-label use, compensation for treating
   their citizens for alleged adverse reactions to RISPERDAL&amp;#174;, civil fines or penalties, punitive
   damages, or other relief. The Attorney General of Texas has joined a qui tam action in that state
   seeking similar relief. Certain of these actions also seek injunctive relief relating to the
   promotion of RISPERDAL&amp;#174;. The Attorneys General of more than 40 other states have indicated a
   potential interest in pursuing similar litigation against the Company&amp;#8217;s subsidiary, Janssen
   Pharmaceutica Inc. (Janssen) (now Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI)), and have
   obtained a tolling agreement staying the running of the statute of limitations while they inquire
   into the issues. In addition, there are six cases filed by union health plans seeking damages for
   alleged overpayments for RISPERDAL&amp;#174;, several of which seek certification as class actions. In the
   case brought by the Attorney General of West Virginia, based on claims for alleged consumer fraud
   as to DURAGESIC&amp;#174; as well as RISPERDAL&amp;#174;, Janssen (now OMJPI) was found liable and damages were
   assessed at $4.5&amp;#160;million. OMJPI has filed an appeal.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Numerous claims and lawsuits in the United States relating to the drug PROPULSID&amp;#174;, withdrawn from
       general sale by the Company&amp;#8217;s Janssen (now OMJPI) subsidiary in 2000, have been resolved or are
       currently enrolled in settlement programs with an aggregate cap below $100&amp;#160;million. Similar
       litigation concerning PROPULSID&amp;#174; is pending in Canada, where a national class action of persons
       alleging adverse reactions to the drug has been certified and a settlement program instituted with
       an aggregate cap below $10&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;AFFIRMATIVE STENT PATENT LITIGATION
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In patent infringement actions tried in Delaware Federal District Court in late 2000, Cordis
       Corporation (Cordis), a subsidiary of Johnson &amp;#038; Johnson, obtained verdicts of infringement and
       patent validity, and damage awards against Boston Scientific Corporation (Boston Scientific) and
       Medtronic AVE, Inc. (Medtronic) based on a number of Cordis vascular stent patents. In December
       2000, the jury in the damage action against Boston Scientific returned a verdict of $324&amp;#160;million
       and the jury in the Medtronic action returned a verdict of $271&amp;#160;million. The Court of Appeals for
       the Federal Circuit has upheld liability in these cases, and on September&amp;#160;30, 2008, the district
       court entered judgments, including interest, in the amounts of $702&amp;#160;million and $521&amp;#160;million
       against Boston Scientific and Medtronic, respectively. Medtronic paid $472&amp;#160;million in October&amp;#160;2008,
       representing the judgment, net of amounts exchanged in settlement of a number of other litigations
       between the companies. The net settlement of $472&amp;#160;million was recorded as a credit to other
   (income)&amp;#160;expense, net in the 2008 consolidated statement of earnings. On September&amp;#160;29, 2009, Cordis
       settled this case with Boston Scientific together with the Kasenthofer/Fontirroche and Ding cases
       described below, for a net payment of $716&amp;#160;million which will be recorded in the fiscal fourth
       quarter of 2009. As part of that settlement Boston Scientific received a paid up license to the
       Fontirroche family of patents worldwide and Cordis received a paid license to the Kastenhofer and
       Ding families of patents worldwide. In addition, in May&amp;#160;2009, Medtronic paid $270&amp;#160;million to
       settle additional patent infringement claims asserted by Cordis based on its vascular stent
       patents, which was recorded as a credit to other (income)&amp;#160;expense, net in the fiscal second quarter
       of 2009.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In January&amp;#160;2003, Cordis filed a patent infringement action against Boston Scientific in Delaware
       Federal District Court accusing its Express2&amp;#8482;, Taxus&amp;#174; and Liberte&amp;#174; stents of infringing the Palmaz
       patent that expired in November&amp;#160;2005. The Liberte&amp;#174; stent was also accused of infringing Cordis&amp;#8217;
       Gray patent that expires in 2016. In June&amp;#160;2005, a jury found that the Express2&amp;#8482;, Taxus&amp;#174; and
       Liberte&amp;#174; stents infringed the Palmaz patent and that the Liberte&amp;#174; stent also infringed the Gray
       patent. On March&amp;#160;31, 2009, the U.S. Court of Appeals for the Federal Circuit affirmed this
       judgment. The case has been remanded to the district court for a trial on damages and willfulness.
   Cordis also filed a lawsuit in Delaware Federal District Court in October of 2008 alleging that
       Boston
   Scientific&amp;#8217;s sale of Taxus&amp;#174; Liberte&amp;#174; since June of 2005 infringes Cordis&amp;#8217; Gray patent.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Cordis has pending several lawsuits in New Jersey and Delaware Federal District Court against
       Guidant Corporation (Guidant), Abbott Laboratories, Inc. (Abbott), Boston Scientific and Medtronic
       alleging that the Xience V&amp;#8482; (Abbott), Promus&amp;#8482; (Boston Scientific) and Endeavor&amp;#174; (Medtronic) drug
       eluting stents infringe several patents owned by or licensed to Cordis.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;PATENT LITIGATION AGAINST VARIOUS JOHNSON &amp;#038; JOHNSON SUBSIDIARIES
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The products of various Johnson &amp;#038; Johnson subsidiaries are the subject of various patent lawsuits,
       the outcomes of which could potentially adversely affect the ability of those subsidiaries to sell
       those products, or require the payment of past damages and future royalties.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In July&amp;#160;2005, a jury in Federal District Court in Delaware found that the Cordis CYPHER&amp;#174; Stent
       infringed Boston Scientific&amp;#8217;s Ding &amp;#8216;536 patent and that the Cordis CYPHER&amp;#174; and BX VELOCITY&amp;#174; Stents
       also infringed Boston Scientific&amp;#8217;s Jang &amp;#8216;021 patent. The jury also found both of those patents
       valid. Boston Scientific seeks substantial damages and an injunction in those actions. Cordis
       appealed. On January&amp;#160;15, 2009, the Court of Appeals for the Federal Circuit held the Ding patent
       invalid. In March of 2009, the Court of Appeals for the Federal Circuit denied Boston Scientific&amp;#8217;s
       motion for reconsideration. On March&amp;#160;31, 2009, the Court of Appeals for the Federal Circuit upheld
       the judgment that Cordis&amp;#8217; CYPHER&amp;#174; stent infringed Boston Scientific&amp;#8217;s Jang patent. The Court of
       Appeals denied Cordis&amp;#8217; application for reconsideration. The case has been remanded for a trial on
       the issues of damages and willfulness. Boston Scientific is not seeking injunctive relief.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In Germany, Boston Scientific has several actions based on its Ding patents pending against the
       Cordis CYPHER&amp;#174; Stent. Cordis was successful in these actions at the trial level, but Boston
       Scientific has appealed. Boston Scientific has brought actions in Belgium, the Netherlands,
       Germany, France and Italy under its Kastenhofer patent, which purports to cover two-layer catheters
       such as those used to deliver the CYPHER&amp;#174; Stent, to enjoin the manufacture and sale of allegedly
       infringing catheters in those countries, and to recover damages. A decision by the lower court in
       the Netherlands in Boston Scientific&amp;#8217;s favor was reversed on appeal in April&amp;#160;2007. Boston
       Scientific has filed an appeal to the Dutch Supreme Court. In October&amp;#160;2007, Boston Scientific
       prevailed in the nullity action challenging the validity of the Kastenhofer patent filed by Cordis
       in Germany. Cordis has appealed. No substantive hearings have been scheduled in the French or
       Italian actions. These cases have been settled as part of the September&amp;#160;29, 2009 settlement
       described above.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Trial in Boston Scientific&amp;#8217;s U.S. case based on the Kastenhofer patent in Federal District Court in
       California concluded in October&amp;#160;2007 with a jury finding that the patent was invalid. The
   jury also found for Cordis on its counterclaim that sale by Boston Scientific of its balloon
       catheters and stent delivery systems infringe Cordis&amp;#8217; Fontirroche patent. The Court has denied
       Boston Scientific&amp;#8217;s post trial motions. On April&amp;#160;9, 2009, the Court ruled that Boston Scientific
       will be required to pay Cordis a royalty of 5.1% of all infringing sales of catheters and stent
       delivery systems from October&amp;#160;2007 as long as they practice the patented invention. The Court
       entered judgment against Boston Scientific in the amount of $26&amp;#160;million. Boston Scientific has
       filed an appeal. This case was settled as part of the September&amp;#160;29, 2009 settlement described
       above.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In May&amp;#160;2008, Centocor, Inc. (Centocor) (now Centocor Ortho Biotech Inc. (COBI)) filed a lawsuit
       against Genentech, Inc. (Genentech) in U.S. District Court for the Central District of California
       seeking to invalidate the Cabilly II patent. Prior to filing suit, Centocor had a sublicense under
       this patent from Celltech (who was licensed by Genentech) for REMICADE&amp;#174; and had been paying
       royalties to Celltech. Centocor has terminated that sublicense and stopped paying royalties.
   Genentech has filed a counterclaim alleging that REMICADE&amp;#174; infringes its Cabilly II patents and
       that the manufacture of REMICADE&amp;#174;, ustekinumab, golimumab and ReoPro infringe one of its patents
       relating to the purification of antibodies made through recombinant DNA techniques. The court has
       scheduled a hearing for Summary Judgment Motions in August&amp;#160;2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In April&amp;#160;2009, a bench trial was held before the Federal District Court for the Middle District of
       Florida on the liability phase of Ciba&amp;#8217;s patent infringement lawsuit alleging that Johnson &amp;#038;
       Johnson Vision Care, Inc.&amp;#8217;s ACUVUE&amp;#174; OASYS&amp;#8482; lenses infringe three of their Nicholson patents. In
       August&amp;#160;2009, the District Court found two of these patents valid and infringed. On October&amp;#160;12,
       2009, Ciba asked the Court to schedule another trial to determine damages and Ciba&amp;#8217;s request for a
       permanent injunction.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In May&amp;#160;2009, Abbott Biotechnology Ltd. filed a patent infringement lawsuit against Centocor (now
       COBI) in the United States District Court for the District of Massachusetts. The suit alleges that
       Centocor&amp;#8217;s SIMPONI&amp;#174; product, a human anti TNF alpha antibody, which was recently approved by the
       FDA, infringes Abbott&amp;#8217;s &amp;#8216;394 patent (the Salfeld patent). The case has been stayed pending the
       resolution of an arbitration filed by Centocor directed to its claim that it is licensed under the
   &amp;#8217;394 patent.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In August&amp;#160;2009, Abbott GmbH &amp;#038; Co. (Abbott GmbH) and Abbott Bioresearch Center filed a patent
       infringement lawsuit against COBI in the United States District Court for the District of
       Massachusetts. The suit alleges that COBI&amp;#8217;s STELARA&amp;#174; product infringes two U.S. Patents assigned
       to Abbott GmbH. In August&amp;#160;2009, COBI filed a complaint for a declaratory judgment of
       non-infringement and invalidity of the Abbott GmbH patents in the United States District Court for
       the District of Columbia. On the same date, also in the United States District Court for the
       District of Columbia, COBI filed a Complaint for Review of a Patent Interference Decision granting
       priority of invention on one of the two asserted patents to Abbott GmbH. In August&amp;#160;2009, Abbott
       GmbH and Abbott Laboratories Limited brought a patent
   infringement suit in Canada alleging that STELARA&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; infringes Abbott GmbH&amp;#8217;s Canadian patent.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In August&amp;#160;2009, Bayer Healthcare LLC filed suit against COBI in Massachusetts District Court
       alleging infringement by COBI&amp;#8217;s SIMPONI&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; product of its patent relating to human anti-TNF
       antibodies. To date, Bayer has not served the complaint on COBI.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In June&amp;#160;2009, Centocor&amp;#8217;s (now COBI) lawsuit alleging that Abbott&amp;#8217;s HUMIRA anti TNF alpha product
       infringes Centocor&amp;#8217;s &amp;#8216;775 patent went to trial in Federal District Court in the Eastern District of
       Texas. On June&amp;#160;28, 2009 a jury returned a verdict finding the patent valid and willfully infringed,
       and awarded Centocor damages of approximately $1.7&amp;#160;billion. All of Abbott&amp;#8217;s post trial motions have
       been denied except that the district court granted Abbott&amp;#8217;s motion to overturn the jury finding of
       willfulness. A bench trial on Abbott&amp;#8217;s defenses, of inequitable conduct and prosecution laches, was
       held on August&amp;#160;4, 2009, and the parties are awaiting decision as to these issues.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The following chart summarizes various patent lawsuits concerning products of Johnson &amp;#038; Johnson
       subsidiaries that have yet to proceed to trial:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="22%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="15%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Plaintiff/&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Trial&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Date&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;J&amp;#038;J Product&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Company&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Patents&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Patent Holder&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Court&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Date&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Filed&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;CYPHER&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; Stent
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Cordis&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Wall&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Wall&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom" nowrap="nowrap"&gt;E.D. TX&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;04/11&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;11/07&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;CYPHER&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; Stent
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Cordis&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Saffran&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Saffran&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;E.D. TX&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;06/11&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;10/07&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Blood Glucose
   Meters and Strips
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Lifescan&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Wilsey&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Roche Diagnostics&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;D. DE&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;11/07&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;REMICADE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;,
   ustekinumab,
   golimumab, ReoPro
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Centocor/ COBI&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Cabilly II&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Genentech&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;C.D. CA&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;05/08&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;SIMPONI&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Centocor/ COBI&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Salfeld&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Abbott Laboratories&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;MA&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;05/09&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;SIMPONI&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Centocor/ COBI&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Boyle&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Bayer Healthcare&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;MA&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;08/09&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;STELARA&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Centocor/ COBI&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Salfeld&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Abbott GmbH&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;MA/DC&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;08/09&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Trial date to be scheduled.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;LITIGATION AGAINST FILERS OF ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The following chart indicates lawsuits pending against generic firms that filed Abbreviated New
       Drug Applications (ANDAs) seeking to market generic forms of products sold by various subsidiaries
       of the Company prior to expiration of the applicable patents covering those products. These ANDAs
       typically include allegations of non-infringement, invalidity and unenforceability of these
       patents. In the event the subsidiary of the Company involved is not successful in these actions, or
       the statutory 30-month stay expires before a ruling from the district court is obtained, the firms
       involved will
   have the ability, upon FDA approval, to introduce generic versions of the product at issue
       resulting in very substantial market share and revenue losses for the product of the Company&amp;#8217;s
       subsidiary.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;As noted in the following chart, 30-month stays expired during 2006, 2007 and 2008, and will expire
       in 2009, 2010 and 2011 with respect to ANDA challenges regarding various products:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="43%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="18%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="6%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Brand Name&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Patent/NDA&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Generic&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Trial&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;Date&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;30-Month&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Product&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Holder&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Challenger&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Court&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Date&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Filed&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;Stay Expiration&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;CONCERTA&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;
   18, 27, 36 and 54 mg
   controlled release tablet
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;McNeil-PPC ALZA&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Andrx&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom" nowrap="nowrap"&gt;D. DE&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;12/07&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;09/05&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;None&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;LEVAQUIN&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; 250, 500, 750 mg tablet
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Ortho-McNeil&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Lupin&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;D. NJ&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;10/06&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;03/09&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;ORTHO TRI-CYCLEN&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; LO
   0.18 mg/0.025 mg, 0.215 mg/
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Ortho-McNeil&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Watson&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;D. NJ&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;10/08&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;03/11&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;0.025 mg and
   0.25 mg/ 0.025 mg
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Sandoz&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;D. NJ&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;06/09&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;10/11&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
   &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;ULTRAM&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; ER 100, 200, 300 mg tablet
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Ortho-&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Par&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;D. DE&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;01/09&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;05/07&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;09/09&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;McNeil/Biovail&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;06/07&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;11/09&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;10/07&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;03/10&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
   &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;ULTRAM&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; ER 100, 200, 300 mg tablet
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Ortho-&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;Impax&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;D. DE&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;06/10&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;08/08&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;01/11&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;McNeil/Biovail&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;11/08&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="bottom"&gt;03/11&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Trial date to be scheduled.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In the action against Barr Pharmaceuticals, Inc. (Barr)(now a wholly-owned subsidiary of Teva
       Pharmaceutical Industries LTD.) regarding ORTHO TRI-CYCLEN&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; LO, on January&amp;#160;22, 2008, the Company&amp;#8217;s
       subsidiary Ortho Women&amp;#8217;s Health &amp;#038; Urology, a Division of Ortho-McNeil-Janssen Pharmaceuticals,
       Inc., and Barr agreed to a non-binding term sheet to settle the litigation, which settlement
       discussions are still underway. The trial court postponed the January&amp;#160;22, 2008 trial without
       setting a new trial date. On June&amp;#160;30, 2009, Barr launched its generic product &amp;#8220;at risk&amp;#8221; before
       trial. OMJPI sought a preliminary injunction and recall of Barr product which the Court granted on
       July&amp;#160;21, 2009. On July&amp;#160;23, 2009, the parties entered into a definitive agreement to settle the
       lawsuit. Under the terms of the settlement, Barr obtained a release for its sales of its generic
       product in exchange for an undisclosed royalty payment. Barr also obtained a non-exclusive,
       royalty-bearing license to re-enter the market on December&amp;#160;31, 2015, or earlier in certain limited
       circumstances.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In October&amp;#160;2008, the Company&amp;#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey
       against Watson Laboratories, Inc. (Watson) in response to Watson&amp;#8217;s ANDA regarding ORTHO
       TRI-CYCLEN&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; LO.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In June&amp;#160;2009, the Company&amp;#8217;s subsidiary OMJPI filed suit in Federal District Court in New Jersey
       against Sandoz Laboratories, Inc. (Sandoz) in response to Sandoz&amp;#8217;s ANDA regarding ORTHO
       TRI-CYCLEN&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; LO.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In the action against Barr and AlphaPharm with respect to their ANDA challenges to the RAZADYNE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;
   patent that Janssen (now OMJPI) licenses from Synaptech, Inc. (Synaptech), a four-day non-jury
       trial was held in the Federal District Court in Delaware in May&amp;#160;2007. On August&amp;#160;27, 2008, the
       court held that the patent was invalid because it was not enabled. Janssen (OMJPI)&amp;#160;and Synaptech
       have appealed the decision. Since the court&amp;#8217;s decision, multiple generic companies have received
       final approvals for their products and have launched &amp;#8220;at risk&amp;#8221; pending appeal. Additional generic
       approvals and launches could occur at any time. On September&amp;#160;25, 2009, the Court of Appeals
       affirmed the judgment that the patent is invalid.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In the action by McNEIL-PPC, Inc. (McNeil-PPC) and ALZA Corporation (ALZA)&amp;#160;against Andrx
       Corporation (Andrx) with respect to its ANDA challenge to the CONCERTA&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; patents, a five-day
       non-jury trial was held in the Federal District Court in Delaware in December&amp;#160;2007. On March&amp;#160;30,
       2009, the court ruled that one CONCERTA&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; patent would not be infringed by Andrx&amp;#8217;s proposed generic
       product and that the patent was invalid because it was not enabled. The court dismissed without
       prejudice Andrx&amp;#8217;s declaratory judgment suit on a second patent for lack of
       jurisdiction. McNeil-PPC and ALZA filed an appeal on May&amp;#160;7, 2009.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In the RAZADYNE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; ER cases, a lawsuit was filed against Barr on the RAZADYNE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; use patent that
       Janssen (now OMJPI) licenses from Synaptech in June&amp;#160;2006. In September&amp;#160;2008, the above-discussed
       Delaware decision invalidating the RAZADYNE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; use patent resulted in entry of judgment for Barr on
       that patent, but the case will be reopened if Janssen (now OMJPI) and Synaptech win on appeal. Barr
       has received FDA approval of its product and has launched &amp;#8220;at risk.&amp;#8221; On September&amp;#160;25, 2009, the
       Federal Circuit affirmed the Delaware decision invalidating the Razadyne&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; use patent. As a result,
       this case will not be reopened.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In the action against Lupin Pharmaceuticals, Inc. (Lupin) regarding its ANDA concerning LEVAQUIN&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;,
       Lupin contends that the United States Patent and Trademark Office improperly granted a patent term
       extension to the patent that Ortho-McNeil (now Ortho-McNeil-Janssen Pharmaceuticals, Inc.
   (OMJPI)) licenses from Daiichi Pharmaceuticals, Inc. (Daiichi). Lupin alleges that the active
       ingredient in LEVAQUIN&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; was the subject of prior marketing, and therefore was not eligible for the
       patent term extension. Lupin concedes validity and that its product would violate the patent if
       marketed prior to the expiration of the original patent term. Summary judgment against Lupin was
       granted in May&amp;#160;2009 and Lupin appealed. Oral argument was held on September&amp;#160;8, 2009.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In the ULTRAM&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; ER actions, Ortho-McNeil Pharmaceutical, Inc. (Ortho-McNeil) (now OMJPI), filed
       lawsuits (each for different dosages) against Par Pharmaceuticals, Inc. and Par Pharmaceuticals
   Companies, Inc. (Par) in May, June and October&amp;#160;2007 on two
       Tramadol ER formulation patents owned by Purdue Pharma Products L.P. (Purdue) and Napp
       Pharmaceutical Group Ltd. (Napp). OMJPI also filed lawsuits (each for different dosages) against
       Impax Laboratories, Inc. (Impax) on a Tramadol ER formulation patent owned by Purdue and Napp in
       August and November&amp;#160;2008. Purdue, Napp and Biovail Laboratories International SRL (Biovail)(the NDA
       holder) joined as co-plaintiffs in the lawsuits against Par and Impax, but Biovail and OMJPI were
       subsequently dismissed for lack of standing. The trial against Par took place on April&amp;#160;16-22, 2009.
   On August&amp;#160;14, 2009, the Court issued a decision finding the patents-in-suit invalid. Purdue has
       appealed that decision. The trial against Impax is scheduled for June&amp;#160;2010. In September and
       October&amp;#160;2009, respectively, Purdue filed suits against Paddock Laboratories, Inc. (Paddock) and
       Cipher Pharmaceuticals Inc. (Cipher) on its tramadol ER formulation patents.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;AVERAGE WHOLESALE PRICE (AWP)&amp;#160;LITIGATION
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;Johnson &amp;#038; Johnson and several of its pharmaceutical subsidiaries, along with numerous other
       pharmaceutical companies, are defendants in a series of lawsuits in state and federal courts
       involving allegations that the pricing and marketing of certain pharmaceutical products amounted to
       fraudulent and otherwise actionable conduct because, among other things, the companies allegedly
       reported an inflated Average Wholesale Price (AWP)&amp;#160;for the drugs at issue. Many of these cases,
       both federal actions and state actions removed to federal court, have been consolidated for
       pre-trial purposes in a Multi-District Litigation (MDL)&amp;#160;in Federal District Court in Boston,
       Massachusetts. The plaintiffs in these cases include classes of private persons or entities that
       paid for any portion of the purchase of the drugs at issue based on AWP, and state government
       entities that made Medicaid payments for the drugs at issue based on AWP.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The MDL Court identified classes of Massachusetts-only private insurers providing &amp;#8220;Medi-gap&amp;#8221;
       insurance coverage and private payers for physician-administered drugs where payments were based on
       AWP (&amp;#8220;Class&amp;#160;2&amp;#8221; and &amp;#8220;Class&amp;#160;3&amp;#8221;), and a national class of individuals who made co-payments for
       physician-administered drugs covered by Medicare (&amp;#8220;Class&amp;#160;1&amp;#8221;). A trial of the two Massachusetts-only
       class actions concluded before the MDL Court in December&amp;#160;2006. In June&amp;#160;2007, the MDL Court issued
       post-trial rulings, dismissing the Johnson &amp;#038; Johnson defendants from the case regarding all claims
       of Classes 2 and 3, and subsequently of Class&amp;#160;1 as well. Plaintiffs appealed the Class&amp;#160;1 judgment
       and, in September&amp;#160;2009, the Court of Appeals vacated the judgment and remanded for further
       proceedings in the District Court. AWP cases brought by various Attorneys General have proceeded to
       trial against other manufacturers. Cases including Johnson &amp;#038; Johnson subsidiaries have been set for
       trial in 2010 and thereafter.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;OTHER
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In July&amp;#160;2003, Centocor (now COBI), a Johnson &amp;#038; Johnson subsidiary, received a request that it
       voluntarily provide documents and information to the criminal division of the U.S. Attorney&amp;#8217;s
       Office, District of New Jersey, in connection with its investigation into various Centocor
       marketing practices. Subsequent requests for documents have been received from the U.S. Attorney&amp;#8217;s
       Office. Both the Company and Centocor have responded to these requests for documents and
       information.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In December&amp;#160;2003, Ortho-McNeil (now OMJPI) received a subpoena from the U.S. Attorney&amp;#8217;s Office in
       Boston, Massachusetts seeking documents relating to the marketing, including alleged off-label
       marketing, of the drug TOPAMAX&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; (topiramate). Additional subpoenas for documents have been
       received, and current and former employees have testified before a grand jury. Discussions are
       underway in an effort to resolve this matter, but whether agreement can be reached and on what
       terms are uncertain.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In January&amp;#160;2004, Janssen (now OMJPI) received a subpoena from the Office of the Inspector General
       of the U.S. Office of Personnel Management seeking documents concerning sales and marketing of, any
       and all payments to physicians in connection with sales and marketing of, and clinical trials for,
       RISPERDAL&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; (risperidone)&amp;#160;from 1997 to 2002. Documents subsequent to 2002 have also been requested.
   An additional subpoena seeking information about marketing of and adverse reactions to RISPERDAL&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;
   was received from the U.S. Attorney&amp;#8217;s Office for the Eastern District of Pennsylvania in
       November&amp;#160;2005. Subpoenas seeking testimony from various witnesses before a grand jury have also
       been received. Janssen is cooperating in responding to ongoing requests for documents and
       witnesses.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In September&amp;#160;2004, Ortho Biotech Inc. (Ortho Biotech)(now COBI), received a subpoena from the U.S.
   Office of Inspector General&amp;#8217;s Denver, Colorado field office seeking documents directed to the sales
       and marketing of PROCRIT&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; (Epoetin alfa) from 1997 to the present, as well as to dealings with U.S.
   Oncology Inc., a healthcare services network for oncologists. Ortho Biotech (now COBI) has
       responded to the subpoena.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In September&amp;#160;2004, plaintiffs in an employment discrimination litigation initiated against the
       Company in 2001 in Federal District Court in New Jersey moved to certify a class of all African
       American and Hispanic salaried employees of the Company and its affiliates in the U.S., who were
       employed at any time from November&amp;#160;1997 to the present. Plaintiffs seek monetary damages for the
       period 1997 through the present (including punitive damages) and equitable relief. The Court denied
       plaintiffs&amp;#8217; class certification motion in December&amp;#160;2006 and their motion for reconsideration in
       April&amp;#160;2007. Plaintiffs sought to appeal these decisions and, in April&amp;#160;2008, the Court of Appeals
       ruled that plaintiffs&amp;#8217; appeal of the denial of class certification was untimely. In July&amp;#160;2009,
       plaintiffs filed a motion for certification of a modified class, which the Company will oppose.
   Plaintiffs are engaged in further discovery of individual plaintiffs&amp;#8217; claims.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In March&amp;#160;2005, DePuy Orthopaedics, Inc. (DePuy), a Johnson &amp;#038; Johnson subsidiary, received a
       subpoena from the U.S. Attorney&amp;#8217;s Office, District of New Jersey, seeking records concerning
       contractual relationships between DePuy and surgeons or surgeons-in-training involved in hip and
       knee replacement and reconstructive surgery. This investigation was resolved by DePuy and the four
       other leading suppliers of hip and knee implants in late September&amp;#160;2007 by agreements with the U.S.
   Attorney&amp;#8217;s Office for the District of New Jersey. The settlements included an 18-month Deferred
       Prosecution Agreement (DPA), acceptance by each company of a monitor to assure compliance with the
       DPA and, with respect to four of the five companies, payment of settlement monies and entry into
       five year Corporate Integrity Agreements. DePuy paid $85&amp;#160;million as its settlement. The term of the
       Monitorship under the Deferred Prosecution Agreement concluded on March&amp;#160;27, 2009, and an order
       dismissing all charges was entered on March&amp;#160;30, 2009.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In November&amp;#160;2007, the Attorney General of the Commonwealth of Massachusetts issued a civil
       investigative demand to DePuy seeking information regarding financial relationships between a
       number of Massachusetts-based orthopedic surgeons and providers and DePuy. DePuy is responding to
       Massachusetts&amp;#8217; additional requests.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In July&amp;#160;2005, Scios Inc. (Scios), a Johnson &amp;#038; Johnson subsidiary, received a subpoena from the U.S.
   Attorney&amp;#8217;s Office, District of Massachusetts, seeking documents related to the sales and marketing
       of NATRECOR&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;. Scios is responding to the subpoena. In early August&amp;#160;2005, Scios was advised that the
       investigation would be handled by the U.S. Attorney&amp;#8217;s Office for the Northern District of
       California in San Francisco. Additional requests for documents have been received and responded to
       and former Scios employees have testified before a grand jury in San Francisco. The qui tam
       complaints were unsealed on February&amp;#160;19, 2009. The U.S. government has intervened in one of the qui
       tam actions, and filed a complaint against Scios and the Company in June&amp;#160;2009. Scios and Johnson &amp;#038;
       Johnson have filed a motion to dismiss the qui tam complaint filed by the government, and that
       motion is pending.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In September&amp;#160;2005, the Company received a subpoena from the U.S. Attorney&amp;#8217;s Office, District of
       Massachusetts, seeking documents related to sales and marketing of eight drugs to Omnicare, Inc., a
       manager of pharmaceutical benefits for long-term care facilities. The Johnson &amp;#038; Johnson
       subsidiaries involved responded to the subpoena. Several employees of the Company&amp;#8217;s pharmaceutical
       subsidiaries have been subpoenaed to testify before a grand jury in connection with this
       investigation. In April&amp;#160;2009, the Company was served with the complaints in two civil qui
       tam cases relating to marketing of prescription drugs to Omnicare, Inc. The complaints assert
       claims under the federal False Claims Act and related state statutes in connection with
       the marketing of several drugs to Omnicare. The government has not yet announced whether it will
       intervene in these cases.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In November&amp;#160;2005, Amgen Inc. (Amgen) filed suit against Hoffmann-LaRoche, Inc. (Roche) in the U.S.
   District Court for the District
       of Massachusetts seeking a declaration that the Roche product CERA, which Roche has indicated it
       would seek to introduce into the United States, infringes a number of Amgen patents concerning EPO.
   Amgen licenses EPO for sale in the United States to Ortho Biotech (now COBI) for non-dialysis
       indications. Trial in this action concluded in October&amp;#160;2007 with a verdict in Amgen&amp;#8217;s favor,
       finding the patents valid and infringed. The judge issued a preliminary injunction blocking the
       CERA launch, and subsequently made the injunction permanent. The Federal Circuit upheld the
       entry of a permanent injunction.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In February&amp;#160;2006, the Company received a subpoena from the U.S. Securities &amp;#038; Exchange Commission
   (SEC)&amp;#160;requesting documents relating to the participation by several Johnson &amp;#038; Johnson subsidiaries
       in the United Nations Iraq Oil for Food Program. The subsidiaries are cooperating with the SEC and
       U.S. Department of Justice (DOJ)&amp;#160;in producing responsive documents.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In February&amp;#160;2007, the Company voluntarily disclosed to the DOJ and the SEC that subsidiaries
       outside the United States are believed to have made improper payments in connection with the sale
       of medical devices in two small-market countries, which payments may fall within the jurisdiction
       of the Foreign Corrupt Practices Act (FCPA). In the course of continuing dialogues with the
       agencies, other issues potentially rising to the level of FCPA violations in additional markets
       have been brought to the attention of the agencies by the Company. The Company has provided and
       will continue to provide additional information to the DOJ and SEC, and will cooperate with the
       agencies&amp;#8217; reviews of these matters. Law enforcement agencies of a number of other countries are
       also pursuing investigations of matters voluntarily disclosed by the Company to the DOJ and SEC.
   Discussions are underway in an effort to resolve these matters, and the Iraq Oil for Food matter
       referenced above, but whether agreement can be reached and on what terms is uncertain.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In March&amp;#160;2007, the Company received separate subpoenas from the U.S. Attorney&amp;#8217;s Office in
       Philadelphia, the U.S. Attorney&amp;#8217;s Office in Boston and the U.S. Attorney&amp;#8217;s Office in San Francisco.
   The subpoenas relate to investigations by these three offices referenced above concerning,
       respectively, sales and marketing of RISPERDAL&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; by Janssen (now OMJPI), TOPAMAX&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; by Ortho-McNeil
   (now OMJPI) and NATRECOR&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; by Scios. The subpoenas request information regarding the Company&amp;#8217;s
       corporate supervision and oversight of these three subsidiaries, including their sales and
       marketing of these drugs. The Company responded to these requests. In addition, the U.S. Attorney&amp;#8217;s
       office in Boston has issued subpoenas for grand jury testimony to several employees of Johnson &amp;#038;
       Johnson.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In May&amp;#160;2007, the New York State Attorney General issued a subpoena seeking information relating to
       the marketing and safety of PROCRIT&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;. The Company is responding to these requests.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In April&amp;#160;2007, the Company received two subpoenas from the Office of the Attorney General of the
       State of Delaware. The subpoenas
   seek documents and information relating to nominal pricing
       agreements. For purposes of the subpoenas, nominal pricing
       agreements are defined as agreements under which the Company agreed to provide a pharmaceutical
       product for less than ten percent of the Average Manufacturer Price for the product. The Company
       responded to these requests.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In January&amp;#160;2008, the European Commission (&amp;#8220;EC&amp;#8221;) began an industry-wide antitrust inquiry concerning
       competitive conditions within the pharmaceutical sector. Because this is a sector inquiry, it is
       not based on any specific allegation that the Company has violated EC competition law. The inquiry
       began with unannounced raids of a substantial number of pharmaceutical companies throughout Europe,
       including Johnson &amp;#038; Johnson affiliates. In March&amp;#160;2008, the EC issued detailed questionnaires to
       approximately 100 companies, including Johnson &amp;#038; Johnson affiliates. In November&amp;#160;2008, the EC
       issued a preliminary report summarizing its findings. The final report was issued on July&amp;#160;8, 2009.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In March&amp;#160;2008, the Company received a letter request from the Attorney General of the State of
       Michigan. The request seeks documents and information relating to nominal price transactions. The
       Company is responding to the request and will cooperate with the inquiry.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In June&amp;#160;2008, the Company received a subpoena from the United States Attorneys Office for the
       District of Massachusetts relating to the marketing of biliary stents by the Company&amp;#8217;s Cordis
       subsidiary. Cordis is cooperating in responding to the subpoena.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In September&amp;#160;2008, Multilan AG (Multilan), an indirect subsidiary of Schering-Plough Corporation,
       commenced arbitration against Janssen Pharmaceutica NV for an alleged wrongful termination of an
       agreement relating to payments in connection with termination of certain marketing rights. Multilan
       seeks declaratory relief, specific performance and damages. Multilan alleges that damages exceed
   &amp;#8364;700&amp;#160;million. A hearing on the matter is scheduled for January&amp;#160;2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In February&amp;#160;2009, Basilea Pharmaceutica AG (Basilea) brought an arbitration against the Company and
       various affiliates alleging that the Company breached the 2005 License Agreement for ceftobiprole
       by, among other things, failing to secure FDA approval of the cSSSI (skin)&amp;#160;indication and allegedly
       failing to properly develop the pneumonia indication. Basilea is seeking to recover damages and a
       declaration that the Company materially breached the agreement.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In April&amp;#160;2009, the Company received a HIPPA subpoena from the U.S. Attorney&amp;#8217;s Office for the
       District of Massachusetts (Boston) seeking information regarding the Company&amp;#8217;s financial
       relationship with several psychiatrists.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In April&amp;#160;2009, Ortho-Clinical Diagnostics, Inc. (OCD)&amp;#160;received a grand jury subpoena from the U.S.
   Department of Justice, Antitrust Division, requesting documents and information for the period
       beginning September&amp;#160;1, 2000 through the present, pertaining to an
   investigation of alleged
       violations of the antitrust laws in the blood reagents industry. The company is in the process of
       complying with the subpoena. In the weeks following the public announcement that OCD had received a
       subpoena from the Antitrust Division, multiple class action complaints were filed. The various
       cases were consolidated for pre-trial purposes in the Eastern District of Pennsylvania.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In May&amp;#160;2009, the New Jersey Attorney General issued a subpoena to DePuy Orthopaedics, Inc., seeking
       information regarding financial interest of clinical investigators who performed clinical studies
       for DePuy Orthopaedics, Inc. and DePuy Spine, Inc.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In May&amp;#160;2009, COBI commenced an arbitration proceeding before the American Arbitration Association
       against Schering-Plough Corporation and its subsidiary Schering-Plough (Ireland) Company
   (collectively, Schering-Plough). COBI and Schering-Plough are parties to a series of agreements
   (the Distribution Agreements) that grant Schering-Plough the exclusive right to distribute the
       drugs REMICADE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; and SIMPONI&amp;#8482; worldwide, except within the United States, Japan, Taiwan, Indonesia,
       and the People&amp;#8217;s Republic of China (including Hong Kong) (the &amp;#8220;Territory&amp;#8221;). COBI distributes
       REMICADE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; and SIMPONI&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt;, the next generation treatment, within the United States. In the
       arbitration, COBI seeks a declaration that the agreement and plan of merger between Merck &amp;#038; Co.,
       Inc. (Merck) and Schering-Plough constitutes a change of control under the terms of the
       Distribution Agreements that permits COBI to terminate the Agreements. The termination of the
       Distribution Agreements would return to COBI the right to distribute REMICADE&lt;font style="font-family: Symbol"&gt;&amp;#226;&lt;/font&gt; and SIMPONI&amp;#8482; within
       the Territory. Schering-Plough has filed a response to COBI&amp;#8217;s arbitration demand that denies both
       that it has undergone a change of control and that it will undergo a change of control upon the
       completion of the merger with Merck. The arbitrators have been selected and the matter will be
       proceeding to arbitration.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;In recent years the Company has received numerous requests from a variety of United States
       Congressional Committees to produce information relevant to ongoing congressional inquiries. It is
       the Company&amp;#8217;s policy to cooperate with these inquiries by producing the requested information.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;With respect to all the above matters, the Company and its subsidiaries are vigorously contesting
       the allegations asserted against them and otherwise pursuing defenses to maximize the prospect of
       success. The Company and its subsidiaries involved in these matters continually evaluate their
       strategies in managing these matters and, where appropriate, pursue settlements and other
       resolutions where those are in the best interest of the Company.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The Company is also involved in a number of other patent, trademark and other lawsuits incidental
       to its business. The ultimate legal and financial liability of the Company in respect to all
       claims, lawsuits and proceedings referred to above cannot be estimated with any certainty. However,
       in the Company&amp;#8217;s opinion, based on its examination of these matters, its experience to date and
       discussions with counsel, the ultimate outcome of
   legal proceedings, net of liabilities accrued in
       the Company&amp;#8217;s balance sheet, is not expected to have a material adverse effect
       on the Company&amp;#8217;s financial condition, although the resolution in any reporting period of one or
       more of these matters could have a significant impact on the Company&amp;#8217;s results of operations and
       cash flows for that period.
   &lt;/div&gt;
   &lt;/div&gt;
</jnj:LegalProceedingsTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:ScheduleOfSubsequentEventsTextBlock contextRef="December-29-2008_September-27-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 13 - us-gaap:ScheduleOfSubsequentEventsTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;NOTE 13-SUBSEQUENT EVENTS
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;
   On November 3, 2009 the Company announced global restructuring
   initiatives that are expected to generate pre-tax, annual cost
   savings of $1.4-$1.7 billion when fully implemented in 2011, with
   $0.8-$0.9 billion expected to be achieved in 2010. The associated
   savings will provide additional resources to invest in new growth
   platforms; ensure the successful launch of its many new products and
   continued growth of its core businesses; and provide flexibility to
   adjust to the changed and evolving global environment. The Company
   expects to take associated pre-tax, restructuring charges in the
   range of $1.1-$1.3 billion in  the fourth quarter of 2009.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;On October&amp;#160;1, 2009 the Company received $716&amp;#160;million from Boston Scientific to settle several stent
   patent litigations. See note 12 for additional details.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;On September&amp;#160;28, 2009 the Company, through its affiliate, has entered into a strategic
   collaboration with Crucell N.V. which will focus on the discovery, development and
   commercialization of monoclonal antibodies and vaccines for the treatment and prevention of
   influenza and other infectious and non-infectious diseases. In addition, Johnson &amp;#038; Johnson, through
   its affiliate, purchased approximately 18% of Crucell&amp;#8217;s outstanding ordinary shares for an
   aggregate purchase price of $448&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 6pt"&gt;The Company has performed an evaluation of subsequent events through November&amp;#160;4, 2009, the date the
   Company issued these financial statements.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:ScheduleOfSubsequentEventsTextBlock>
  <!-- End Block Tagged Note -->
  <dei:AmendmentFlag contextRef="December-29-2008_September-27-2009">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="December-29-2008_September-27-2009">--01-03</dei:CurrentFiscalYearEndDate>
  <dei:DocumentPeriodEndDate contextRef="December-29-2008_September-27-2009">2009-09-27</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="December-29-2008_September-27-2009">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="December-29-2008_September-27-2009">0000200406</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_25Oct2009" unitRef="Shares" decimals="INF">2759099726</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="December-29-2008_September-27-2009">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="December-29-2008_September-27-2009">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="December-29-2008_September-27-2009">JOHNSON &amp; JOHNSON</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="December-29-2008_September-27-2009">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="December-29-2008_September-27-2009">Yes</dei:EntityWellKnownSeasonedIssuer>
  <jnj:AccruedRebatesReturnsAndPromotions contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">2237000000</jnj:AccruedRebatesReturnsAndPromotions>
  <jnj:AccruedRebatesReturnsAndPromotions contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">2123000000</jnj:AccruedRebatesReturnsAndPromotions>
  <jnj:CostOfGoodsSoldPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">29.1</jnj:CostOfGoodsSoldPercentageIncreaseDecrease>
  <jnj:CostOfGoodsSoldPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">30</jnj:CostOfGoodsSoldPercentageIncreaseDecrease>
  <jnj:CostOfGoodsSoldPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">29</jnj:CostOfGoodsSoldPercentageIncreaseDecrease>
  <jnj:CostOfGoodsSoldPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">29.4</jnj:CostOfGoodsSoldPercentageIncreaseDecrease>
  <jnj:GrossProfitPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">70.9</jnj:GrossProfitPercentageIncreaseDecrease>
  <jnj:GrossProfitPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">70</jnj:GrossProfitPercentageIncreaseDecrease>
  <jnj:GrossProfitPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">71</jnj:GrossProfitPercentageIncreaseDecrease>
  <jnj:GrossProfitPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">70.6</jnj:GrossProfitPercentageIncreaseDecrease>
  <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">27.6</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease>
  <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">26.9</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease>
  <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">29</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease>
  <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">28.2</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsPercentageIncreaseDecrease>
  <jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">6.5</jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease>
  <jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">6.1</jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease>
  <jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">6.8</jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease>
  <jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">6</jnj:IncomeTaxExpenseBenefitPercentageIncreaseDecrease>
  <jnj:InterestExpensePercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">0.7</jnj:InterestExpensePercentageIncreaseDecrease>
  <jnj:InterestExpensePercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">0.8</jnj:InterestExpensePercentageIncreaseDecrease>
  <jnj:InterestExpensePercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">0.8</jnj:InterestExpensePercentageIncreaseDecrease>
  <jnj:InterestExpensePercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">0.9</jnj:InterestExpensePercentageIncreaseDecrease>
  <jnj:InvestmentIncomeInterestPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">-0.6</jnj:InvestmentIncomeInterestPercentageIncreaseDecrease>
  <jnj:InvestmentIncomeInterestPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">-0.6</jnj:InvestmentIncomeInterestPercentageIncreaseDecrease>
  <jnj:InvestmentIncomeInterestPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">-0.2</jnj:InvestmentIncomeInterestPercentageIncreaseDecrease>
  <jnj:InvestmentIncomeInterestPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">-0.2</jnj:InvestmentIncomeInterestPercentageIncreaseDecrease>
  <jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">-0.8</jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease>
  <jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">-1.4</jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease>
  <jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">-0.4</jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease>
  <jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">-0.6</jnj:OtherNonOperatingIncomeExpensePercentageIncreaseDecrease>
  <jnj:PrepaidExpensesAndOtherReceivables contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">3367000000</jnj:PrepaidExpensesAndOtherReceivables>
  <jnj:PrepaidExpensesAndOtherReceivables contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">2768000000</jnj:PrepaidExpensesAndOtherReceivables>
  <jnj:ProfitLossPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">21.1</jnj:ProfitLossPercentageIncreaseDecrease>
  <jnj:ProfitLossPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">20.8</jnj:ProfitLossPercentageIncreaseDecrease>
  <jnj:ProfitLossPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">22.2</jnj:ProfitLossPercentageIncreaseDecrease>
  <jnj:ProfitLossPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">22.2</jnj:ProfitLossPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">11.3</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">11.7</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">10.5</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">10.7</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">0.1</jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">0</jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">0</jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease>
  <jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">0</jnj:ResearchAndDevelopmentInProcessPercentageIncreaseDecrease>
  <jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">100</jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease>
  <jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">100</jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease>
  <jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">100</jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease>
  <jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">100</jnj:SalesRevenueGoodsNetPercentageIncreaseDecrease>
  <jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">32.6</jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease>
  <jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Pure" decimals="2">32.6</jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease>
  <jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="Pure" decimals="2">31.3</jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease>
  <jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Pure" decimals="2">31.6</jnj:SellingGeneralAndAdministrativeExpensePercentageIncreaseDecrease>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">7503000000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">6419000000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">9719000000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">10279000000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">417000000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">1029000000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">5531000000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">4862000000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">13027000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">14637000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">-4955000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">-2661000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">268000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">316000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:Assets contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">84912000000</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">91558000000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">34377000000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">35602000000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">2041000000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">2481000000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">4000000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">19000000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Dec2007" unitRef="USD" decimals="-6">7770000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_28Sep2008" unitRef="USD" decimals="-6">14018000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">10768000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">11856000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">6248000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">1088000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommonStockDividendsPerShareCashPaid contextRef="NineMonthsEnded_28Sep2008" unitRef="USDEPS" decimals="3">1.335</us-gaap:CommonStockDividendsPerShareCashPaid>
  <us-gaap:CommonStockDividendsPerShareCashPaid contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USDEPS" decimals="3">0.46</us-gaap:CommonStockDividendsPerShareCashPaid>
  <us-gaap:CommonStockDividendsPerShareCashPaid contextRef="December-29-2008_September-27-2009" unitRef="USDEPS" decimals="3">1.44</us-gaap:CommonStockDividendsPerShareCashPaid>
  <us-gaap:CommonStockDividendsPerShareCashPaid contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USDEPS" decimals="3">0.49</us-gaap:CommonStockDividendsPerShareCashPaid>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="INF">1</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="INF">1</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_28Dec2008" unitRef="Shares" decimals="INF">4320000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_27Sep2009" unitRef="Shares" decimals="INF">4320000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_28Dec2008" unitRef="Shares" decimals="INF">3119843000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_27Sep2009" unitRef="Shares" decimals="INF">3119843000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">3120000000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">3120000000</us-gaap:CommonStockValue>
  <us-gaap:CostOfGoodsSold contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">14139000000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">4774000000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">13135000000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">4434000000</us-gaap:CostOfGoodsSold>
  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">7791000000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">7111000000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-354000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">541000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">3430000000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">2650000000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">5841000000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">5888000000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">1432000000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">1505000000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">2117000000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">2030000000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasic contextRef="NineMonthsEnded_28Sep2008" unitRef="USDEPS" decimals="2">3.64</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USDEPS" decimals="2">1.19</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="December-29-2008_September-27-2009" unitRef="USDEPS" decimals="2">3.64</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USDEPS" decimals="2">1.21</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="NineMonthsEnded_28Sep2008" unitRef="USDEPS" decimals="2">3.6</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USDEPS" decimals="2">1.17</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="December-29-2008_September-27-2009" unitRef="USDEPS" decimals="2">3.61</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USDEPS" decimals="2">1.2</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-56000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">208000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">1432000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">1471000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:Goodwill contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">13719000000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">15017000000</us-gaap:Goodwill>
  <us-gaap:GrossProfit contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">34426000000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">11147000000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">32211000000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">10647000000</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">13412000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">4290000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">13151000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">4245000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">3177000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">980000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">3091000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">900000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-1103000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">-1830000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-790000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">-61000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-348000000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">-250000000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-2000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">-35000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">590000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">291000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">13976000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">16636000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestExpense contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">325000000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">122000000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">358000000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">142000000</us-gaap:InterestExpense>
  <us-gaap:InventoryNet contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">5052000000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">5568000000</us-gaap:InventoryNet>
  <us-gaap:InvestmentIncomeInterest contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">268000000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">97000000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">78000000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">28000000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:Liabilities contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">42401000000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">41174000000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">84912000000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">91558000000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">20852000000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">19245000000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">8120000000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">8259000000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-2994000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">-5170000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">-1673000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">-5234000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">10971000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">11284000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed contextRef="BalanceAsOf_28Sep2008" unitRef="USD" decimals="-6">400000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed>
  <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">2337000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed>
  <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired contextRef="BalanceAsOf_28Sep2008" unitRef="USD" decimals="-6">416000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired>
  <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">3193000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired>
  <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed contextRef="BalanceAsOf_28Sep2008" unitRef="USD" decimals="-6">-16000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed>
  <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">-856000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed>
  <us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">2630000000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">3581000000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">4206000000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">5054000000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">377000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">224000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">165000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">96000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">36000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">163000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">5773000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">1172000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsOfOrdinaryDividends contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">3750000000</us-gaap:PaymentsOfOrdinaryDividends>
  <us-gaap:PaymentsOfOrdinaryDividends contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">3974000000</us-gaap:PaymentsOfOrdinaryDividends>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">400000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">2337000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireInvestments contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">1434000000</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:PaymentsToAcquireInvestments contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">5922000000</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">1938000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">1521000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">1640000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">9000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">2079000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">4697000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
  <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">56000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">12000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:ProceedsFromShortTermDebt contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">5194000000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:ProceedsFromShortTermDebt contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">3903000000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">1360000000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">300000000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProfitLoss contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">10235000000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">3310000000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">10060000000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">3345000000</us-gaap:ProfitLoss>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">27392000000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">29452000000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">14365000000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">14815000000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">62000000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">39000000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">16000000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">224000000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfShortTermDebt contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">1649000000</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:RepaymentsOfShortTermDebt contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">4012000000</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">5469000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">1861000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">4773000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">1617000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">40000000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">0</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">63379000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">69471000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SalesRevenueGoodsNet contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">48565000000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">15921000000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">45346000000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">15081000000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">15825000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">5195000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">14172000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_27Sep2009" unitRef="USD" decimals="-6">4767000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="NineMonthsEnded_28Sep2008" unitRef="USD" decimals="-6">524000000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="December-29-2008_September-27-2009" unitRef="USD" decimals="-6">499000000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShortTermBorrowings contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">3732000000</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">3341000000</us-gaap:ShortTermBorrowings>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">42511000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">50384000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:TreasuryStockShares contextRef="BalanceAsOf_28Dec2008" unitRef="Shares" decimals="INF">350665000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares contextRef="BalanceAsOf_27Sep2009" unitRef="Shares" decimals="INF">361821040</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="BalanceAsOf_28Dec2008" unitRef="USD" decimals="-6">19033000000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue contextRef="BalanceAsOf_27Sep2009" unitRef="USD" decimals="-6">19546000000</us-gaap:TreasuryStockValue>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="NineMonthsEnded_28Sep2008" unitRef="Shares" decimals="-5">2847800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Shares" decimals="-5">2831300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="December-29-2008_September-27-2009" unitRef="Shares" decimals="-5">2787900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Shares" decimals="-5">2793000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="NineMonthsEnded_28Sep2008" unitRef="Shares" decimals="-5">2811900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_28Sep2008" unitRef="Shares" decimals="-5">2790900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="December-29-2008_September-27-2009" unitRef="Shares" decimals="-5">2760000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_27Sep2009" unitRef="Shares" decimals="-5">2756300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Footnote Section-->
</xbrl>
